JP2020511115A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020511115A5 JP2020511115A5 JP2019533166A JP2019533166A JP2020511115A5 JP 2020511115 A5 JP2020511115 A5 JP 2020511115A5 JP 2019533166 A JP2019533166 A JP 2019533166A JP 2019533166 A JP2019533166 A JP 2019533166A JP 2020511115 A5 JP2020511115 A5 JP 2020511115A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- transcription factor
- acid sequence
- car
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000007523 nucleic acids Chemical class 0.000 claims description 42
- 108091023040 Transcription factor Proteins 0.000 claims description 28
- 102000040945 Transcription factor Human genes 0.000 claims description 28
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 22
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 22
- 102000039446 nucleic acids Human genes 0.000 claims description 18
- 108020004707 nucleic acids Proteins 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 102100021631 B-cell lymphoma 6 protein Human genes 0.000 claims description 2
- 101000971234 Homo sapiens B-cell lymphoma 6 protein Proteins 0.000 claims description 2
- 101000687344 Homo sapiens PR domain zinc finger protein 1 Proteins 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 102100024894 PR domain zinc finger protein 1 Human genes 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 230000004186 co-expression Effects 0.000 claims description 2
- 230000004069 differentiation Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000012636 effector Substances 0.000 claims description 2
- 230000035772 mutation Effects 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 230000002463 transducing effect Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022126972A JP2022145846A (ja) | 2016-12-21 | 2022-08-09 | Ｃａｒおよび転写因子を発現する細胞、ならびにその使用 |
| JP2024114672A JP2024133286A (ja) | 2016-12-21 | 2024-07-18 | Ｃａｒおよび転写因子を発現する細胞、ならびにその使用 |
| JP2024114673A JP2024133287A (ja) | 2016-12-21 | 2024-07-18 | Ｃａｒおよび転写因子を発現する細胞、ならびにその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1621889.3 | 2016-12-21 | ||
| GBGB1621889.3A GB201621889D0 (en) | 2016-12-21 | 2016-12-21 | Cell |
| PCT/GB2017/053834 WO2018115865A1 (en) | 2016-12-21 | 2017-12-20 | Cell expressing a car and a transcription factor and its use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022126972A Division JP2022145846A (ja) | 2016-12-21 | 2022-08-09 | Ｃａｒおよび転写因子を発現する細胞、ならびにその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020511115A JP2020511115A (ja) | 2020-04-16 |
| JP2020511115A5 true JP2020511115A5 (enExample) | 2020-12-03 |
| JP7149273B2 JP7149273B2 (ja) | 2022-10-06 |
Family
ID=58284380
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019533166A Active JP7149273B2 (ja) | 2016-12-21 | 2017-12-20 | Ｃａｒおよび転写因子を発現する細胞、ならびにその使用 |
| JP2022126972A Withdrawn JP2022145846A (ja) | 2016-12-21 | 2022-08-09 | Ｃａｒおよび転写因子を発現する細胞、ならびにその使用 |
| JP2024114673A Pending JP2024133287A (ja) | 2016-12-21 | 2024-07-18 | Ｃａｒおよび転写因子を発現する細胞、ならびにその使用 |
| JP2024114672A Pending JP2024133286A (ja) | 2016-12-21 | 2024-07-18 | Ｃａｒおよび転写因子を発現する細胞、ならびにその使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022126972A Withdrawn JP2022145846A (ja) | 2016-12-21 | 2022-08-09 | Ｃａｒおよび転写因子を発現する細胞、ならびにその使用 |
| JP2024114673A Pending JP2024133287A (ja) | 2016-12-21 | 2024-07-18 | Ｃａｒおよび転写因子を発現する細胞、ならびにその使用 |
| JP2024114672A Pending JP2024133286A (ja) | 2016-12-21 | 2024-07-18 | Ｃａｒおよび転写因子を発現する細胞、ならびにその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20200030379A1 (enExample) |
| EP (1) | EP3559213A1 (enExample) |
| JP (4) | JP7149273B2 (enExample) |
| CN (1) | CN110099997A (enExample) |
| AU (1) | AU2017380449B2 (enExample) |
| CA (1) | CA3047621C (enExample) |
| GB (1) | GB201621889D0 (enExample) |
| WO (1) | WO2018115865A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220127570A1 (en) * | 2018-05-03 | 2022-04-28 | Cafa Therapeutics Limited | Immune effector cell and use thereof |
| WO2019243817A1 (en) * | 2018-06-19 | 2019-12-26 | Autolus Limited | Cell |
| WO2020183131A1 (en) | 2019-03-08 | 2020-09-17 | Autolus Limited | Compositions and methods comprising engineered chimeric antigen receptor and modulator of car |
| US20220169687A1 (en) | 2020-11-10 | 2022-06-02 | Kyverna Therapeutics, Inc. | Method for treating disease using foxp3+cd4+ t cells |
| CN114805596B (zh) * | 2021-01-22 | 2023-07-14 | 华东师范大学 | 一种以磷脂酰肌醇聚糖3为靶点的嵌合抗原受体及其应用 |
| CN116997563A (zh) | 2021-01-27 | 2023-11-03 | 莱尔免疫制药股份有限公司 | 改良的免疫细胞疗法 |
| WO2022165419A1 (en) | 2021-02-01 | 2022-08-04 | Kyverna Therapeutics, Inc. | Methods for increasing t-cell function |
| WO2022183076A1 (en) | 2021-02-25 | 2022-09-01 | Lyell Immunopharma, Inc. | Enhanced immune cell therapy targeting ny-eso-1 |
| WO2022182890A1 (en) | 2021-02-25 | 2022-09-01 | Lyell Immunopharma, Inc. | Codon-optimized nucleotide sequences encoding an ap-1 transcription factor |
| AU2022227686A1 (en) | 2021-02-25 | 2023-07-27 | Lyell Immunopharma, Inc. | Ror1 targeting chimeric antigen receptor |
| EP4347826A1 (en) | 2021-06-02 | 2024-04-10 | Lyell Immunopharma, Inc. | Nr4a3-deficient immune cells and uses thereof |
| CA3234826A1 (en) | 2021-10-28 | 2023-05-04 | Lyell Immunopharma, Inc. | Methods for culturing cells expressing c-jun |
| JP2024540099A (ja) | 2021-10-28 | 2024-10-31 | ライエル・イミュノファーマ・インコーポレイテッド | Ｒｏｒ１結合タンパク質を発現する細胞を培養する方法 |
| WO2023212566A1 (en) * | 2022-04-25 | 2023-11-02 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for preventing t cell exhaustion |
| AU2023273885A1 (en) | 2022-05-19 | 2024-12-05 | Lyell Immunopharma, Inc. | Polynucleotides targeting nr4a3 and uses thereof |
| WO2024020429A1 (en) | 2022-07-22 | 2024-01-25 | Lyell Immunopharma, Inc. | Immune cell therapy |
| WO2024064958A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| WO2024064952A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells overexpressing c-jun |
| WO2024077174A1 (en) | 2022-10-05 | 2024-04-11 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| WO2025217398A1 (en) | 2024-04-10 | 2025-10-16 | Lyell Immunopharma, Inc. | Methods for culturing cells with improved culture medium |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3783098A1 (en) | 2013-05-14 | 2021-02-24 | Board Of Regents, The University Of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| WO2016168595A1 (en) | 2015-04-17 | 2016-10-20 | Barrett David Maxwell | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
| GB201509413D0 (en) | 2015-06-01 | 2015-07-15 | Ucl Business Plc | Fusion protein |
| WO2017035251A1 (en) * | 2015-08-25 | 2017-03-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cells modified to overexpress c-myb |
| US10188749B2 (en) * | 2016-04-14 | 2019-01-29 | Fred Hutchinson Cancer Research Center | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers |
| US12060394B2 (en) * | 2016-04-28 | 2024-08-13 | The Trustees Of Dartmouth College | Nucleic acid constructs for co-expression of chimeric antigen receptor and transcription factor, cells containing and therapeutic use thereof |
-
2016
- 2016-12-21 GB GBGB1621889.3A patent/GB201621889D0/en not_active Ceased
-
2017
- 2017-12-20 AU AU2017380449A patent/AU2017380449B2/en active Active
- 2017-12-20 WO PCT/GB2017/053834 patent/WO2018115865A1/en not_active Ceased
- 2017-12-20 CN CN201780079674.7A patent/CN110099997A/zh active Pending
- 2017-12-20 US US16/470,968 patent/US20200030379A1/en not_active Abandoned
- 2017-12-20 CA CA3047621A patent/CA3047621C/en active Active
- 2017-12-20 JP JP2019533166A patent/JP7149273B2/ja active Active
- 2017-12-20 EP EP17822745.0A patent/EP3559213A1/en active Pending
-
2022
- 2022-08-09 JP JP2022126972A patent/JP2022145846A/ja not_active Withdrawn
-
2023
- 2023-11-30 US US18/525,271 patent/US20240307440A1/en active Pending
-
2024
- 2024-07-18 JP JP2024114673A patent/JP2024133287A/ja active Pending
- 2024-07-18 JP JP2024114672A patent/JP2024133286A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020511115A5 (enExample) | ||
| AU2019227813B2 (en) | Neoantigen identification with pan-allele models | |
| ES3029080T3 (en) | Neoantigen identification using hotspots | |
| US11446398B2 (en) | Regulated biocircuit systems | |
| JP7395483B2 (ja) | ｍＲＮＡの細胞内送達のためのペプチドおよびナノ粒子 | |
| US20190005191A1 (en) | Chromosome neighborhood structures and methods relating thereto | |
| JP2019525914A5 (enExample) | ||
| KR20190112271A (ko) | 난소암 및 다른 암에 대한 면역요법에 사용을 위한 신규 펩티드 및 펩티드의 조합 | |
| ITMI20071522A1 (it) | Vaccino idiotipico | |
| JP2021502102A5 (enExample) | ||
| JPWO2019156137A5 (enExample) | ||
| JP7026970B2 (ja) | 白血病およびその他のがんに対する免疫療法において使用するためのペプチドおよびペプチドの組み合わせ | |
| JP2020501574A5 (enExample) | ||
| JPWO2019202322A5 (enExample) | ||
| Yuan et al. | Structure and function of vimentin in the generation and secretion of extracellular vimentin in response to inflammation | |
| JP2012527440A5 (enExample) | ||
| JP2016082979A5 (enExample) | ||
| JP2017525357A5 (enExample) | ||
| JP2004290197A5 (enExample) | ||
| Choi et al. | Nuclear ribonucleoprotein condensates as platforms for gene expression regulation | |
| JP2009511036A5 (enExample) | ||
| JP2022502081A (ja) | 遺伝子操作された微生物ならびにそれを作製および使用する方法 | |
| Raghavan | Engineering minimally immunogenic cargos and delivery modalities for gene therapy | |
| Perez-Maya et al. | Complete genome sequence of Streptococcus pneumoniae serotype 19A, a blood clinical isolate from Northeast Mexico | |
| JPWO2021079122A5 (enExample) |